Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric AML transplantation conditioning regimen study
NL-OMON58759Phase 3Recruiting
- Sponsor
- Region Västra Götaland
- Start
- Mar 2024
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in acute myeloid leukemia (AML) comparing Busulfan + clofarabine + fludarabine with Busulfan + cyclophosphamide + melphalan (2 arms). Primary endpoint: 2-year GVHD-free, relapse-free survival. Started Mar 2024; status: recruiting.
02
Drugs
busulfanclofarabinefludarabinecyclophosphamidemelphalan
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON58759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58759.